Treatment failure mainly occurs in children affected by metastases from high-risk medulloblastomas, which are characterized by aberrations of chromosome 17, mostly deletion of 17p and gain of 17q with LASP1 being one of the most upregulated genes on chromosome 17q in tumors with 17q gain. The gene discussed is LASP1; the disease is medulloblastoma.